Pitango Venture Capital

Chemi Peres and Rami Kalish are co-founders and managing partners and still anchor the firm. The managing partner group spans the three practices: Eyal Niv and Ayal Itzkovitz on Pitango First, Isaac Hillel on Growth, and Ittai Harel and Hila Karah on HealthTech, alongside Aaron Mankovski. Yair Cassuto and Gad Huldai are general partners on the First team. Eyal Klein is chief financial officer and was named personally on the HealthTech Fund II offering; Zeev Binman preceded him as CFO. The operating bench includes Ofira Kadmor as senior vice president of finance, Elana Barzilay as head of legal, Vered Digmy in investor relations and Maria Ginzburg on capital partnerships. Venture partners add international reach and sector depth: chairman Dan Charash, Pascal Cagni, Amir Faintuch and Dr. Seth Rudnick, with Jonathan Glazer, a physician, on the HealthTech team.

Pitango says it has raised 13 funds, manages more than $3 billion and has backed over 300 companies with more than 100 exits, making it Israel's largest and longest-standing venture platform. Its US Form D filings trace the flagship series: Fund VI in August 2012, Fund VII in December 2016, Fund VIII in January 2020 and Fund IX in March 2023, each filed with an indefinite offering amount, which is why headline sizes for the core funds are not disclosed in SEC records.

The specialist vehicles do disclose numbers. Pitango Growth Fund I filed in October 2015 and Growth Fund II sold $194.5 million after a first sale in March 2020. Pitango HealthTech Fund I sold $131.5 million following a May 2019 first sale, and HealthTech Fund II sold $111.3 million after starting to raise in February 2023. Pitango also organized a continuation fund in 2021 and a series of co-investment SPVs. The platform now runs as three distinct practices: Pitango First for seed and early stage, Pitango Growth, and Pitango HealthTech.